CAR-TCR 2023 – Josh Ludwig

Innovation was the watchword at CAR-TCR in Boston last month, but one of the limitations of innovation is that it can be challenging for an industry to transition from the rapid iteration stage to the long haul.

And while the research side of cell therapy might still be casting a wide net, for these therapies to get to patients the business side needs to get serious about efficiency, consistency, and scaling.

At the event, editor-in-chief Jonah Comstock caught up with Josh Ludwig, global director at ScaleReady, a joint venture to improve cell and gene therapy manufacturing. In the video below, Josh discusses how the industry needs to start moving from pure innovation to building efficient, sustainable infrastructure - simple, standardised workflows that can be scaled and automated.

“The race should be not who can be the most innovative, but who can treat more patients,” Josh says.

They also get into the manufacturing commonalities between allogeneic and autologous therapies, how to flexibly serve both markets, and the tension between competition and cooperation in an emerging field like cell and gene therapy.

Check out the full video below.